|Bid||64.52 x 1100|
|Ask||103.31 x 1300|
|Day's Range||62.45 - 64.65|
|52 Week Range||56.13 - 93.89|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for LIVN
LivaNova PLC ( NASDAQ:LIVN ), might not be a large cap stock, but it received a lot of attention from a substantial...
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
ALung Technologies Inc., whose HemoLung product developed out of the University of Pittsburgh helps patients with acute respiratory distress, has been acquired by a London-based medical technology company. LivaNova (NASDAQ: LIVN) acquired ALung for $10 million with additional payments on sales-based milestones in the future, according to LivaNova's first-quarter earnings report that was released Wednesday. "ALung products are complementary to LivaNova's ACS portfolio and, as such, the business and financial results will be included in the company's ACS (Advanced Circulatory Support) segment," LivaNova said.